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Abstract
The X-linked genetic bleeding disorder caused by deficiency of
coagulator factor IX, hemophilia B, is a disease ideally suited for
gene therapy with genome editing technology. Here, we identify a
family with hemophilia B carrying a novel mutation, Y371D, in the
human F9 gene. The CRISPR/Cas9 system was used to generate
distinct genetically modified mouse models and confirmed that
the novel Y371D mutation resulted in a more severe hemophilia B
phenotype than the previously identified Y371S mutation. To
develop therapeutic strategies targeting this mutation, we subse-
quently compared naked DNA constructs versus adenoviral vectors
to deliver Cas9 components targeting the F9 Y371D mutation in
adult mice. After treatment, hemophilia B mice receiving naked
DNA constructs exhibited correction of over 0.56% of F9 alleles in
hepatocytes, which was sufficient to restore hemostasis. In
contrast, the adenoviral delivery system resulted in a higher
corrective efficiency but no therapeutic effects due to severe
hepatic toxicity. Our studies suggest that CRISPR/Cas-mediated
in situ genome editing could be a feasible therapeutic strategy for
human hereditary diseases, although an efficient and clinically
relevant delivery system is required for further clinical studies.
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Introduction
Hemophilia B (HB), an X-linked genetic bleeding disorder caused by
deficiency of coagulator factor IX (FIX), affects 1 of every 25,000 to
30,000 males worldwide (Thompson & Chen, 1993). Based on the
FIX plasma procoagulant levels, the disease is classified as mild
(5–40% of normal activity), moderate (1–5% of normal activity),
and severe (< 1% of normal activity; White et al, 2001). As solely
increasing the plasma FIX levels as low as 1% results in significant
restoration of clotting activity, HB is considered a good model for
evaluating the efficacy of distinct gene therapy strategies. Introduc-
ing the F9 gene cDNA into the liver (the natural source of FIX secre-
tion) of HB animal models and patients through recombinant
adeno-associated virus (rAAV) has proven to be efficacious (Kay
et al, 1993, 2000; Snyder et al, 1997; Nathwani et al, 2014), but two
major concerns remain: the duration of expression and the safety
issue of AAV-mediated random insertion of the transgene into the
host genome. Sleeping Beauty transposon-induced random insertion
of the FIX transgene in HB mice has shown that integration into the
host genome is feasible for long-term and high-level FIX expression
(Yant et al, 2000). Recent studies demonstrated that site-specific
integration of human F9 cDNA into transcriptionally highly active
genomic loci in hepatocytes through either a nuclease (zinc finger
nuclease) dependent or independent manner successfully amelio-
rated the disease in mice (Li et al, 2011; Anguela et al, 2013; Barzel
et al, 2015). These strategies theoretically overcome the significant
concerns of transgene expression duration and random insertion-
induced safety issue, but whether direct correction of the F9 muta-
tion by targeting the endogenous locus is sufficient for restoration
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of clotting activity through somatic genome editing is still not
determined.
The CRISPR/Cas9 system developed from an RNA-mediated
adaptive immune system identified in bacteria is a revolutionary
technology for gene editing in cells and organisms (Jinek et al,
2012; Cong et al, 2013; Hwang et al, 2013; Li et al, 2013; Mali
et al, 2013; Shen et al, 2013; Wang et al, 2013; Doudna &
Charpentier, 2014; Niu et al, 2014). Cas9/sgRNA induces site-
specific DNA double-strand breaks (DSBs) which then initiate
either error-prone non-homologous end joining (NHEJ) or homol-
ogy-directed repair (HDR) in the presence of donor DNA
templates (Cong et al, 2013; Mali et al, 2013). Pioneer studies
have shown potential applications of the CRISPR/Cas9 system
for correction of genetic disorders in cells or mouse embryos
(Schwank et al, 2013; Wu et al, 2013; Long et al, 2014), as well
as prevention of cardiovascular disease in adult mice through
disruption of the PCSK9 gene (Ding et al, 2014). Recently, a
mouse model of hereditary tyrosinemia type I(HT1)caused by a
point mutation of fumarylacetoacetate hydrolase (FAH) was
phenotypically restored via Cas9-mediated gene repair in vivo (Yin
et al, 2014). In this particular model, the repaired cells had a
survival advantage and expanded to replace the mutant hepato-
cytes when the pharmacological inhibitor NTBC was withdrawn
(Yin et al, 2014). As the initial correction rate in the model is
lower to 0.4%, it is essential to investigate the efficacy of Cas9-
mediated in vivo genetic correction of other heritable diseases in
which the repaired cells cannot be easily selected for repopulation.
Here, we identify a family with HB carrying a novel FIX mutation
which is confirmed as an HB causative mutation through generation
of mice with an identical mutation via the CRISPR/Cas9 system.
Delivery of the Cas9 component in vivo resulted in correction of
over 0.56% of endogenous F9 alleles in hepatocytes and restored
hemostasis in mice. Our data strongly demonstrate that correction
of genetic disorders through repair of mutations in situ via CRISPR/
Cas9-mediated genome editing is feasible.
Results
Identification of novel F9 mutation in HB patients
A 9-year-old male proband (Fig 1A IV:2) was diagnosed HB with
an abnormal activated partial thromboplastin time (aPTT) of
84 s (reference values: 25 s ~35 s) with a normal factor VIII
activity. His clotting activity was remarkably decreased to about
2% of the normal level (Table 1). By taking a detailed family
history, five patients were identified in the pedigree (Fig 1A). A
single missense mutation in exon 8 of F9 was identified in all
tested patients. The mutation causes a thymidine-to-guanine
transversion at nucleotide position 31094, replacing tyrosine with
aspartate at amino acid 371 (Fig 1B). This mutation is a novel
variation which has not been reported either in the Hemophilia
B Mutation Database (http://www.factorix.org/; Thompson &
Chen, 1993) or the Human Gene Mutation Database (HGMD,
http://www.hgmd.cf.ac.uk/ac/index.php), although a 31095A>C
variation has been reported in HGMD leading to a Y371S muta-
tion causing mild HB (20% of normal FIX activity). As residue
371 is located in the highly conserved serine protease domain
(Fig 1C), we decided to generate mouse models containing the
corresponding mutations to further confirm the phenotype as
well as to explore the potential of CRISPR/Cas9-mediated
genome editing for amelioration of HB in mice.
Generation and characterization of F9 mutant mouse strains
We employed the Cas9 system as previously described (Shao et al,
2014) to introduce a precise point mutation in the mouse F9 locus
corresponding to human amino acid residue 371 (position 381 in
mouse FIX, Fig 1C). After injection of Cas9 components and distinct
donor templates into mouse zygotes (Fig 2A), three mouse strains,
respectively, bearing the novel mutant site F9Y381D and two previ-
ously reported sites (F9Y381S and F9383STOP) were generated (Fig 2B
and Appendix Fig S1). No off-target cleavage was detected through
T7E1 analysis and sequencing of the 10 most likely potential
off-target sites (Appendix Fig S2). The F9 mRNA level in liver tissue
was not impaired in F9Y381D and F9Y381S mice but significantly
decreased in F9383STOP mice since the premature stop codon dramat-
ically affects mRNA stability (Fig 2C). Consistently, the protein level
was almost invisible in F9383STOP mice but not in F9Y381D mice
compared to wild-type controls (Fig 2C), suggesting that the Y381D
mutation does not influence actual FIX levels and stability. The
average aPTT for 8-week-old wild-type mice was 22.04  0.77 s
(n = 5), but aPTTs were prolonged to 41.78  1.18 s and
45.684  1.10 s for the F9383STOP (n = 5) and the F9Y381D (n = 5)
mouse strains, respectively (Fig 2D). The aPTT for the F9Y381S strain
was not significantly increased (aPTT = 22.71  1.17 s; n = 5;
Fig 2D) which was consistent with observations in humans. No
significant difference of average prothrombin time (PT) was
observed in 8-week-old wild-type, F9Y381S, F9Y381D, and F9383STOP
mouse strains (Fig 2E). The prolonged aPTT and the normal PT
demonstrated that the F9Y381D and F9383STOP mouse strains gener-
ated in this study are models for HB. Additionally, these strains
were subjected to a tail-clip challenge for further confirmation of
defects in hemostasis. The blood loss volume of the 4 strains of mice
in 5 min after tail-clip was recorded as shown in Fig 2F. F9383STOP
mice (n = 5) lost more than 10 times the volume of blood lost by
wild-type controls (n = 5), but no significant difference was
observed between wild-type controls and F9Y381S (n = 6) or F9Y381D
mice (n = 13), suggesting that the Y381D mutation does not cause
very severe HB in mice. However, the survival rate of F9383STOP
and F9Y381D mice was significantly decreased in the two days after
the tail-clip challenge (Fig 2G). Taken together, these data indicate
the successful generation of HB mouse models and suggest that
the Y381D and 383STOP mutations dramatically disrupted FIX
activity.
Restoration of hemostasis in HB mice through naked DNA
injection of Cas9 components
To explore whether correction of a mutated F9 gene in situ can
restore clotting activity in adult HB mice, we employed CRISPR/
Cas9 system-mediated genome editing. As DNA-based vectors do
not have viral contaminants and almost no immunogenicity (Kay,
2011), we first explored hydrodynamic tail vein (HTV) injection, a
sophisticated strategy for in vivo gene delivery in animals. The
pX458 plasmid containing Cas9-2A-GFP components (Fig 3A) was
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delivered through our modified HTV injection procedure to test the
transgenic efficiency. Twenty hours after pX458 plasmid injection,
liver tissue was obtained and eGFP expression was detected in
18.2  3.1% of hepatocytes on average (Appendix Fig S3). Donor
templates as either a 120-nt ssODN or a plasmid were delivered with
pX458 through HTV injection (Fig 3A). To prevent donor DNA
cleavage by Cas9/sgRNA, the HDR donor plasmid contains the G>T
corrected nucleotide and 10 synonymous single-nucleotide
exchanges which are flanked by about 400-bp homologous arms on
each side (Fig 3A and E). The average aPTTs for WT and F9Y381D
mutant mice were 22.1  1.75 s and 51.88  2.71 s, respectively
(Fig 3B). Eight weeks after injection of Cas9/ssODN or Cas9/donor
plasmids, the average PT was not affected but aPTTs significantly
dropped to 32.7  2.02 s (P = 0.0004 compared to F9Y381D) and
31.6  4.99 s (P = 0.0046 compared to F9Y381D), respectively




Figure 1. Characterization of a F9 gene mutation in a family with a history of bleeding diathesis.
A Family pedigree. Blackened symbols indicate the patients with hemophilia B; white circles with dots show carriers of the mutation; open symbols indicate healthy
individuals. Circles represent females; squares represent males. The proband is labeled with an arrow.
B The partial sequences of the F9 gene from a healthy subject (left), the patient (middle), and a carrier (right).
C Amino acid alignment of partial sequence of the serine protease domain of FIX in 10 species. An asterisk (*) indicates positions which have a single, fully conserved
residue. A colon (:) indicates conservation between groups of strongly similar properties. A period (.) indicates conservation between groups of weakly similar
properties.
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(px458 + donor)-treated F9Y381D mice was significantly shortened
compared to the mock-treated (mock + donor) group (P = 0.0306),
but had no significant difference compared to the WT group
(P = 0.0892). Similar results were also obtained when we used
ssODN as donor templates (Fig 3B). To further confirm the therapeu-
tic effect, tail-clip challenge assay was performed. The survival rate
was increased from 38% (5 out of 13) in the untreated group to 86%
(12 out of 14) in F9Y381D mice which had received Cas9/donor
plasmid injection (Fig 3C). Our data suggest that Cas9-mediated
hepatic genome editing corrected the F9 mutation in situ and signifi-
cantly restored the coagulation activity of adult F9Y381D mice.
Sequencing analysis of 177 TA-clones suggested that the indel rate
and HDR rate both were 0.56% in the ssODN group (Fig 3D).
Through deep sequencing analysis, the modification efficiency was
determined in the group that received plasmid donor and Cas9/
sgRNA. About 4.39% of F9 alleles were modified, including 2.84%
indel mutations and 1.55% G>T corrections (Fig 3D and E). In three
randomly selected individual mice, the highest HDR rate was 2.84%
with 2.77% indel mutations (Fig 3F), suggesting that the plasmid
donor exhibits a high fidelity of corrective repair. The majority of
HDRs resulted in the desired G>T correction and total or partial
synonymous substitutions (Fig 3E). These data suggested that the
presence of the corrected gene in about 0.56% of endogenous F9 alle-
les is sufficient to restore clotting activity. No significant difference
in blood aspartate transaminase (AST) and alanine transaminase
(ALT) levels between control and naked DNA-injected group was
observed at 8 weeks (Fig 3G), and liver tissues were histologically
normal despite a mild increase of inflammatory cytokine mRNA
levels (Fig 3H), suggesting that HTV injection of naked DNA vectors
was well tolerated in accordance with a previous report (Yin et al,
2014).
Genetic correction of F9 mutation via Cas9 system delivered
through recombinant adenovirus
Next, we sought to increase the transduction efficiency of the Cas9
components to achieve a higher HDR rate in mouse hepatocytes. An
adenoviral (Adv) gene delivery system was employed due to its
large DNA capacity, high efficiency, and non-integration into the
host genome (Crystal, 2014). More importantly, genome editing
using a protein-capped AdV was more accurate than using other
vectors (Holkers et al, 2014). We generated adenoviral Cas9
(AdvCas9) and a vector containing the corrective donor template
following a sgRNA target (AdvG/T; Fig 4A). To test the infection
and editing efficiency, 1 × 1010 and 7 × 1010 vector genomes of
AdvCas9 and AdvG/T were delivered per mouse via tail vein injec-
tion. Four days later, almost all hepatocytes were infected (Fig 4B)
and caused an about 19% mutation frequency detected through
T7E1 assays (Fig 4C and Appendix Table S5). Additionally, no off-
target mutations were detected in hepatocytes (Appendix Fig S4).
To our surprise, the aPTTs were not shortened in F9Y381D mice
8 weeks after treatment in both the low-dose group (1 × 1010 and
1 × 1010 vector genomes of AdvCas9 and AdvG/T) and the high-
dose group (1 × 1010 and 7 × 1010 vector genomes of AdvCas9 and
AdvG/T) compared with untreated F9Y381D mice (Fig 4D). The indel
rate and HDR rate of the low-dose group were both 0.85% according
to sequencing of 237 individual TA-clones (Fig 4E). In high-dose
group, deep sequence analysis suggested that genetically 31.34% of
F9 alleles were targeted through either NHEJ (25.81%) or the HDR
(5.53% G>T correction) pathway (Fig 4E). Further studies demon-
strated dramatically increased plasma AST and ALT levels and the
transcription of inflammatory factors in the high-dose group
(Appendix Fig S5A and B), suggesting that AdVs induced immune
response-mediated hepatic injury (Muruve et al, 1999), which was
confirmed by histology analysis (Appendix Fig S5C). Severe hepatic
toxicity was perhaps mainly due to the high immunogenicity of the
AdV-induced systemic cytokine response. Although low-dose AdV
administration did not stimulate significant inflammation
(Appendix Fig S5), the extremely low genome editing efficiency
suggested that there is still a long way to go to optimize AdV for
curing HB through Cas9-mediated gene correction.




(% of normal level)
Proband (IV2) 2
Proband’s twin brother (IV3) 2
Proband’s non-twin brother (IV1) 70
Proband’s grandfather (II1) 3
Proband’s aunt (III3) 55
Normal FIX activity range (%): > 45
▸Figure 2. Generation and characterization of variant F9 mutant mouse strains.A Schematic diagram of the strategy to generate F9Y381D and F9Y381S mouse strains. Introduced mutant oligonucleotide is in red, and the corresponding amino acids are
in green.
B Sanger sequencing showing the point mutations in F9 mutant strains. Mutated oligonucleotides are indicated by arrows, and the premature stop codon is
underlined.
C Expression of F9 mRNA and protein in hepatic tissue of indicated mouse strains. Data represent means  SE. The significant effect was obtained using the two-tailed
unpaired Student’s t-test to determine the P‐value. M: Marker; arrowhead: FIX protein; Note: the bands of FIX in F9383STOP lanes are faint with small molecular weight
smears. The gel is representative of three independent experiments.
D Measurement of coagulation activity by aPTT in mice at 8 weeks of age. n = 5 for each group, data represent means  SE. P‐value was determined using two-tailed
unpaired Student’s t-test.
E Measurement of coagulation activity by PT in mice at 8 weeks of age. n = 5 for each group, data represent means  SE.
F Measurement of blood loss over a 5-min period after tail transection in mice at 8 weeks of age. Wild-type, n = 5; F9Y381S, n = 6; F9Y381D, n = 13; F9383STOP, n = 5.
P-value was determined using two-tailed unpaired Student’s t-test.
G Survival rate of mice after the tail-clip challenge. The mice were monitored for 2 days after tail clipping. Wild-type, n = 5; F9Y381S, n = 6; F9Y381D, n = 13; F9383STOP, n = 5.
Source data are available online for this figure.
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Discussion
To date, at least 1113 unique F9 mutations, including 812 unique
point mutations, have been identified worldwide (Rallapalli et al,
2013). Here, we report a novel Y371D mutation of the F9 gene and
confirmed a more severe HB phenotype than the previously identi-
fied Y371S mutation suggesting that this single amino acid substitu-
tion dramatically affects FIX activity. To our knowledge, this is the
first report to confirm the FIX activities of distinct patient-derived
mutations in the mouse. Subsequently, we provide the first evidence
demonstrating amelioration of HB in mice through Cas9-mediated
genetic correction in the endogenous F9 locus.
In experiments with HTV injection, the HDR rate was 0.56% in
mice injected with the ssODN donor and 1.5% in the group with the
double-stranded DNA (dsDNA) plasmid donor. It suggests that
correction of 0.5–1.5% of endogenous F9 alleles in hepatocytes is
sufficient to ameliorate hemostasis in HB mice, but the repair effi-
ciency for fully curing HB is not clear. Previous studies suggest that
higher efficiency was achieved when using ssODN as templates
compared to dsDNA in cell culture (Lin et al, 2014). However, in
our study, a higher repair efficiency was observed in the group
using dsDNA as a donor template probably due to the shorter half-
life of ssODN in live animals. The HDR rate through HTV injection
of naked DNA in our study is similar to that reported by Yin and
colleagues (Yin et al, 2014). Although due to the safety issue and
rapid extinction, hydrodynamic injection of a DNA vector is not
considered to be clinical practicable at the present time, modifi-
cations of the procedure for hydrodynamic gene therapy of liver
segments have been achieved in pigs and have been demonstrated
to be safe in a clinical trial (Khorsandi et al, 2008). Since DNA-
based vectors offer several advantages over state-of-the-art
recombinant viral vectors (Kay, 2011), especially their low host
immunogenicity which makes them applicable for repetitive
treatments, the clinical potential of CRISPR/Cas9-mediated genome
editing via hydrodynamic injection holds considerable promise.
Compared with DNA-based vectors, the non-integrating AdV-
mediated gene delivery system significantly increased CRISPR/Cas9
system-mediated genome editing efficiency in vivo. After AdV treat-
ment, 5.5% of mutant F9 alleles were corrected in HB mice, which
is much higher than the rate through HTV injection. However, no
significant restoration of clotting activity was observed in AdV-
treated HB mice in either the high-dose group or the low-dose
group. We were surprised that no therapeutic effect was observed in
the low-dose AdV-treated group. It is probably due to the relatively
low HDR efficiency and an adverse effect of AdV injection on clot-
ting as a previous study suggested that aPTT increased after injec-
tion of helper-dependent AdVs even in healthy mice (Brunetti-Pierri
et al, 2004). It is critical to reduce the side effects of AdV-mediated
gene delivery for further studies of CRISPR/Cas9-mediated gene
therapy. The high efficiency and non-integrating features of AdV
can be used to correct defective cells for ex vivo gene therapy, since
protein-capped AdV donor DNA greatly reduces illegitimate recom-
bination (Holkers et al, 2014). The recombinant adeno-associated
virus (rAAV) system is the state-of-the-art gene delivery system
which has been demonstrated to be safe and effective in FIX defi-
ciency-induced HB patients (Nathwani et al, 2014). Although rAAV-
mediated site-specific repair of a mutated F9 gene has successfully
restored hemostasis in HB mice (Li et al, 2011; Barzel et al, 2015),
it will be valuable to evaluate the genome editing efficiency in an
HB model using rAAV to deliver a short form of Cas9 derived from
◀ Figure 3. Amelioration of HB in F9 mutant mice through naked DNA injection of Cas9 components.A Schematic diagram of plasmids used for treatment in vivo. Cas9 protein and sgRNA were from pX458 vector. The plasmid donor was 800 bp in length in pEASY
vector. The ssODN donor was 120 oligonucleotides.
B Test of clotting activity by aPTT and PT at 8 weeks following hydrodynamic tail vein injection of 120 lg pX458 and 120 lg donor plasmids (or 120 lg ssODN) per
mouse. Data are presented as mean  SE. The experiment was replicated three times. P‐value was determined using two-tailed unpaired Student’s t-test.
C Survival rate of mice after the tail-clip challenge. F9Y381D mice were treated with or without Cas9/sgRNA/donor DNA for 3 months. After tail-clip challenge, the
survival rate of each group over 2 days was determined. Wild-type, n = 9; untreated F9Y381D, n = 13; DNA-treated F9Y381D, n = 14.
D Frequency of genetic modification in F9Y381D hepatocytes was determined either by deep sequencing (Cas9/donor vector-treated group) or by TA-clone sequencing
(Cas9/ssODN group).
E HDR donor design for correction of Y381D and representative Illumina sequencing reads (rn) in DNA-treated HB mice. Red text indicates the correction of mutation,
whereas blue text indicates the synonymous mutations.
F The genome editing efficiency of individual mice is presented.
G Plasma aspartate aminotransferase (AST) and alanine aminotransferase (ALT) level was determined in F9Y381D mice 8 weeks after HTV injection (n = 5). Data are
presented as mean  SE. P‐value was determined using two-tailed unpaired Student’s t-test.
H mRNA levels of inflammatory cytokines from liver tissue of naked DNA-treated mice were determined by real-time PCR. Data represent means  SE. The experiment
was replicated three times. P‐value was determined using two-tailed unpaired Student’s t-test.
Figure 4. Genetic correction of F9 mutation via the Cas9 system delivered through AdV.
A Schematic of AdVs used for in vivo genome editing. AdvCas9: humanized spCas9 is fused to mCherry through 2A peptide. AdvG/T: an 800-bp corrective template and
sgRNA targeting the mouse F9 Y381D mutation was inserted into an AdV containing GFP.
B In vivo infection efficiency 4 days after Adv injection. Inserts: negative control from untreated mouse liver tissue. Scale bar: 100 lm.
C T7E1 assay was performed on liver DNA obtained from samples in (B), and the frequency of Cas9-induced indels is indicated as “%” below the lane.
D Measurement of clotting activity by aPTTs and PTs 8 weeks after tail vein injection with indicated vectors. Data represent means  SE. The experiment was
replicated three times. P‐value was determined using two-tailed unpaired Student’s t-test.
E In vivo genome editing efficiency of whole liver tissues from mice treated with Adv(Cas9 + G/T). (Left) HDR donor used for correction of Y381D mutation, and Illumina
sequencing reads (rn) are presented. Red text indicates the correction of the F9 mutation, whereas blue text indicates the intended synonymous mutations. (Right)
The percentage of indel or HDR corrections obtained through sequencing of 235 individual TA-clones (low dose) or Illumina sequencing (high dose) of treated mouse
liver tissues.
Source data are available online for this figure.
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Staphylococcus aureus (Ran et al, 2015) since CRISPR/Cas9 is the
most efficient genome editing tool currently available. In conclu-
sion, we identified a novel F9 mutation in patients and ameliorated
HB in adult mice through in situ correction of the F9 locus via Cas9-
mediated genome editing. Our approach provides proof of principle
for considering CRISPR/Cas as a versatile tool in precision medicine,
from functional confirmation of genomic variants to the develop-




All participating individuals were informed and gave documented
consent prior to participation. The studies were approved by the
Human Ethics Committee of the Affiliated Hospital of Hainan Medi-
cal University following the principles set out in the WMA Declara-
tion of Helsinki and the Department of the Health and Human
Service Belmont Report. All animal experiments conformed to the
regulations drafted by the Association for Assessment and Accredi-
tation of Laboratory Animal Care in Shanghai and were approved
by the East China Normal University Center for Animal Research.
Patients and mutation analysis
The proband presented to the Affiliated Hospital of Hainan Medical
University, with repeated spontaneous hemorrhage in his left knee
joint, and was diagnosed with hemophilia. Peripheral blood DNA of
the proband, his twin brother, his parents, and some available rela-
tives was collected for genetic studies. The entire coding sequence
of the F9 gene was amplified by polymerase chain reaction (PCR)
using published primers (Chang et al, 2002). The amplified product
was purified using an AxyPrep DNA Gel Extraction Kit (Axygen
Biosciences, USA) and sequenced using ABI 3500 Genetic Analyzer
(Applied Biosystems, Foster City, CA, USA). Sequencing results
were analyzed using BLAST (http://www.ncbi.nlm.nih.gov/blast)
program against the human normal F9 gene sequence (GenBank
Accession No. K02402), and the mutation was compared with the
Human Gene Mutation Database (http://www.biobase-internatio-
nal.com/product/hgmd) and Factor IX Mutation Database (http://
www.factorix.org/). Blood DNA was extracted and sequenced from
100 symptom-free residents in the same community as the proband
to see whether the F9 variant is a DNA polymorphism or disease-
causing mutation.
Generation of the mouse hemophilia B model
The mouse hemophilia B model was generated by co-injection
of Cas9 mRNA, sgRNA (Appendix Table S1), and ssODNs
(Appendix Table S2) as described previously (Shao et al, 2014).
Briefly, superovulated female C57BL/6J mice were mated to male
C57BL/6J mice, and embryos were collected from oviducts. Cas9
mRNA (100 ng/ll), sgRNA targeting the FIX loci (50 ng/ll), and
ssODN carrying the Y381D or Y381S (10 ng/ll) mutations were
co-injected into the pronuclei of one-cell embryos. The injected
embryos were cultured in KSOM overnight before they were
transplanted into pseudopregnant mice. One week after birth,
genomic DNA from the toes or tail of the newborn F0 mice was
extracted for sequencing. Mice were housed in standard cages in a
specific pathogen-free facility on a 12-h light/dark cycle with ad libi-
tum access to food and water.
Adenovirus amplification
Adenoviral Cas9 (AdvCas9) and the corrective adenovirus contain-
ing the donor template and the sgRNA (Appendix Table S1) target
(AdvG/T) were purchased from Obio Technology (Shanghai).
Twenty-four hours before infection, 293A (ATCC) cells were seeded
into 15 dishes (15 cm in diameter) and cultured until 80% conflu-
ency. For each dish, 5 × 108 particles of adenovirus were added and
mixed well. Seventy-two hours later, 1.5 ml 10% Nonidet P40
(NP40) was added into each plate after removing the media and the
cells were dislodged and lysed by pipetting. Cell lysate was centri-
fuged at 13,800 g for 10 min, and the supernatant was collected.
For 100 ml supernatant, 50 ml virus precipitation buffer (20%
PEG8000, 2.5 M NaCl) was added, followed by 1-h incubation on
ice. The virus particles were spun down at 13,800 g for 30 min and
dissolved in 1.10 g/ml CsCl solution (1.32 g CsCl in 10 ml 20 mM
Tris–HCl buffer pH 8.0). A CsCl density gradient was prepared by
sequentially dripping down 8 ml 1.40 g/ml CsCl solution, 12 ml
1.3 g/ml CsCl solution, and 20 ml virus containing solution into a
Beckman Quick-Seal tube (Item No. 342414). The virus was centri-
fuged at 46,000 g in 4°C for 3 h. A concentrated virus band between
1.3 and 1.4 g/ml CsCl solution was collected and dialyzed (20%
sucrose (w/v), 10 mM Tris–HCl and 2 mM MgCl2, pH 8.0) to
remove the CsCl.
Tail vein injection of adenovirus
The injection volume of virus was adjusted to 100 ll with phos-
phate-buffered saline (PBS), pH 7.4 (Gibco). For the high-dose
group, mice (8 to 10 week old) were injected with 1 × 1010 and
7 × 1010 particles of AdvCas9 and AdvG/T, respectively; for the low-
dose group, mice (8 to 10 week old) were randomly grouped and
injected with 1 × 1010 and 1 × 1010 particles of AdvCas9 and AdvG/
T. For the pilot experiment, 4 days after injection, mice were sacri-
ficed by carbon dioxide asphyxiation. Whole liver samples were
harvested and portioned for immunofluorescence, T7E1 assay, and
Sanger sequencing. For the second experiment, 8 weeks after injec-
tion, liver samples were split for H&E staining, inflammatory cytoki-
nes quantification, and HDR detection. Terminal blood samples were
collected for aPTT and the aminotransferase test.
Plasmids construction and hydrodynamic tail vein injection
pSpCas9(BB)-2A-GFP (pX458) was a gift from Feng Zhang (Addgene
plasmid # 48138). The protospacer sequence targeting the Y381D
mouse locus was synthesized from Genewiz and inserted into
pX458 through BbsI. The HDR donor vector was constructed by
insertion of the donor sequence into the pEASY-Blunt Simple vector
(TransGen Biotech). ssODNs (120 nt; Appendix Table S2) carrying
the D381Y were synthesized from Genewiz. Hydrodynamic injection
was performed as described previously (Liu et al, 1999) with minor
modifications. Briefly, all dosages of plasmid solution were diluted
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into 1 ml (final volume) 0.9% NaCl. The tail vein injection was
performed within 5–7s for maximum liver absorption. For the plas-
mid donor group, mice were injected with both pX458 (120 lg) and
pEASY-HDR donor (120 lg); for the ssODN donor group, mice were
injected with pX458 (120 lg) and ssODN-HDR donor (120 lg). The
control group received 1 ml 0.9% NaCl only.
On-target, off-target, and HDR analysis
Dissected mouse liver tissue (0.1 g) was fast frozen in liquid nitro-
gen, homogenized, and digested in lysis buffer (400 mM NaCl,
100 mM Tris–HCl (pH 8.0), 5 mM EDTA, 0.2% SDS, 20 g/ml RNase
A, and 500 g/ml Proteinase K). Liver genome DNA was isolated by
phenol–chloroform extraction. To detect cleavage and HDR effi-
ciency, PCR amplicons of on-target products were subcloned to the
pEASY-blunt vector for sequencing. The number of clones for on-
target analysis of Cas9/ssODN group and low-dose Adv group was
over 100. Off-target prediction was implemented using the CRISPR
design website (http://crispr.mit.edu/). The primers for PCR amplifi-
cation are listed in Appendix Table S3 or Appendix Table S4 as indi-
cated. On-target PCR products of Cas9/donor plasmids group and
high-dose Adv group were subject to deep sequencing. Deep
sequencing libraries were made from 1 to 100 ng of the PCR prod-
ucts using Nextera protocol (Illumina). Libraries were normalized
through quality check and sequenced on Illumina HiSeq 2500/3000
machines (125 bp, paired-end). Every sequencing library produced
10 M reads. Reads were mapped to the PCR amplicons as references.
Data processing was performed according to standard Illumina
sequencing analysis procedures. The high throughput sequence data
from this publication have been submitted to the Sequence Read
Archive database, and the accession number is PRJNA299277.
Immunofluorescence, Western blot, and Real-time PCR
Mouse liver tissues were fixed in 4% paraformaldehyde, dehy-
drated, embedded in OCT, and cryosectioned at 4 lm thickness.
Thereafter, sections were rinsed in PBS to remove the OCT, stained
with DAPI, and sealed using mounting buffer (Sigma-Aldrich). Cas9
and sgRNA expression was indicated by mCherry and GFP, respec-
tively, under the microscope. For Western blot, liver tissue was
homogenized in liquid nitrogen and the total protein content was
released in lysis buffer (50 mM Tris-base (pH 7.4), 150 mM NaCl,
1% Triton X-100, 1% sodium deoxycholate, 0.1% SDS, and
Complete Mini Protease Inhibitor cocktail (Roche)). The expression
of GFP and FIX protein was visualized by anti-GFP antibody (Santa
Cruz) and anti-F9 polyclonal antibody (Protein tech). For qPCR,
liver tissue was homogenized in liquid nitrogen and the total RNA
was isolated with RNAiso Plus (TaKaRa). RT–PCR was performed
with SYBR Green (TaKaRa). The primers for qPCR were listed in
Appendix Table S6.
Aminotransferase test
Mouse plasma was collected by retro-orbital bleeding and stored at
4°C for 30 min. Thereafter, the supernatants of the samples were
collected after centrifuging at 860 g for 10 min at 4°C. The amount
of aminotransferase was measured by the AU680 Chemistry System
(Beckman).
Activated Partial Thromboplastin Time (aPTT) and prothrombin
time (PT) test
Mouse plasma was obtained via retro-orbital bleeding, diluted 9:1
into sodium citrated anticoagulant, followed by gently mixing.
Blood samples were spun at 220 g for 15 min, and the upper layer
was carefully separated from red blood cells for the aPTT and PT
test. The aPTT and PT tests were measured by the CA-1500 auto-
matic blood coagulation analyzer (SYSMEX).
Tail-clip challenge
Mice were anesthetized, and a tail-clip assay was performed as a
previous described (Kung et al, 1998; Park et al, 2015). In brief, the
distal part of the tail at 1.5 mm diameter was cut and allowed to
bleed for 5 min freely. Blood samples were collected, and the total
bleed volume of each mouse was measured. After holding firm pres-
sure on the tail for 1 min, the mice were monitored for 2 days after
clipping and the survival rate of each group was determined.
Statistics
Data are expressed as means  SEM. Means of two groups were
compared using Student’s t-test (unpaired, 2-tailed), with P < 0.05
considered to be statistically significant.
Expanded View for this article is available online.
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Problem
Hemophilia B, an X-linked genetic bleeding disorder caused by defi-
ciency of coagulator factor IX, is a worldwide hematology disease.
Whether direct correction of the F9 mutation by targeting the
endogenous locus is sufficient for restoration of clotting activity
through somatic genome editing is still not determined.
Results
We identify a family with hemophilia B carrying a novel mutation,
Y371D, in the human F9 gene. We used the CRISPR/Cas9 system to
generate distinct genetically modified mouse models and confirmed
that the novel Y371D mutation resulted in a more severe hemophilia
B phenotype than the previously identified Y371S mutation. We subse-
quently deliver Cas9 components targeting the F9 Y371D mutation in
adult mice. Our results show correction of 0.56% of endogenous F9
alleles in hepatocytes, which was sufficient to restore hemostasis in
hemophilia B mice.
Impact
Our studies suggest that CRISPR/Cas9-mediated in situ genome edit-
ing is a feasible therapeutic strategy for hemophilia B and in general
for human hereditary diseases, although an efficient and clinically
relevant delivery system must be developed for clinical use.
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